SCHEMBL4055815

SCHEMBL4055815

CCc1nc(Nc2ccccc2C)nc(N)c1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
LMNA P02545 1/20 0.48
PKM P14618 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
MAPT P10636 10/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 2/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
MEN1 O00255 1/20 0.44
ATM Q13315 1/20 0.44
CDK5 Q00535 2/20 0.44
CDK5R1 Q15078 2/20 0.44
BLM P54132 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4064425 0.87 MAPT (0.47) RAB9ASMN1; SMN2LMNAMAPTPOLB
SCHEMBL4060122 0.87 MAPT (0.63) RAB9ASMN1; SMN2MAPTPOLBKMT2A
SCHEMBL4058064 0.87 MAPT (0.47) RAB9ASMN1; SMN2NPC1LMNAMAPT
SCHEMBL4055995 0.85 MAPT (0.62) RAB9ASMN1; SMN2NPC1MAPTPOLB
SCHEMBL3821604 0.69 MEN1 (0.45) RAB9ASMN1; SMN2NPC1LMNAMAPT
SCHEMBL4055825 0.68 KMT2A (0.65) RAB9ANPC1LMNAMAPTPOLB
SCHEMBL13750837 0.68 HTT (0.59) RAB9ASMN1; SMN2NPC1LMNAPKM
SCHEMBL20355764 0.68 NPC1 (0.76) RAB9ASMN1; SMN2NPC1LMNANFKB1
SCHEMBL4064433 0.68 MAPK1 (0.48) RAB9ANPC1LMNAMAPTPOLB
SCHEMBL4060127 0.68 MAPK1 (0.48) RAB9ANPC1LMNAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550473-B2 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-06-23 US disclosed
EP-1590334-A1 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-11-02 EP disclosed
US-20050124640-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004067516-A1 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124640-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta PRKCQ, PRKCZ, PRKCH RAB9A 1799/4885SMN1; SMN2 3852/4885NPC1 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.